Clinical Trial Detail

NCT ID NCT04106843
Title Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endocrine Cancers
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

pituitary cancer

parathyroid carcinoma

thyroid gland medullary carcinoma

paraganglioma

pheochromocytoma

Therapies

lutetium Lu 177 dotatate

Age Groups: adult senior

No variant requirements are available.